EGFR-TKI resistant non-small cell lung cancer (NSCLC): New developments and implications for future treatment

被引：61

作者：

Brugger, Wolfram ^{[1
]}

Thomas, Michael ^{[2
]}

机构：

[1] Univ Freiburg, Acad Teaching Hosp, Schwarzwald Baar Clin, Dept Hematol Oncol,Med Ctr 2, Villingen Schwenningen, Germany

[2] Heidelberg Univ, Thoraxklin Heidelberg, Heidelberg, Germany

来源：

LUNG CANCER | 2012年 / 77卷 / 01期

关键词：

Afatinib; EGFR mutation; EGFR-TKI; MetMAb; Tivantinib; NSCLC; Secondary resistance; TYROSINE KINASE INHIBITORS; RANDOMIZED PHASE-II; ERLOTINIB PLUS PLACEBO; ACQUIRED-RESISTANCE; CLINICAL-TRIAL; GEFITINIB; DISCONTINUATION; MULTICENTER; RETREATMENT; LAPATINIB;

D O I：

10.1016/j.lungcan.2011.12.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Treatment with receptor-tyrosine kinase inhibitors (TKIs) has improved progression-free and overall survival in patients with advanced non-small cell lung cancer (NSCLC). One major target for treatment with TKI is the epidermal growth factor receptor (EGFR), particularly in patients harboring activating mutations. However, despite initial responses and long lasting remissions, the development of secondary resistance inevitably leads to treatment failure. Analyzing recent data from various phase II/III trials it seems obvious that the single mode of action of gefitinib or erlotinib can provide temporary success only. Both preclinical and clinical evidence suggest that irreversible TKIs such as afatinib or PF00299804, or combined approaches using multiple kinase inhibition (e.g. EGFR and MET) and vertical inhibition by combination of small molecules and antibodies, seem to be more promising and will be the prevailing concepts to overcome secondary EGFR-TKI resistance for the near future. (C) 2011 Elsevier Ireland Ltd. All rights reserved.

引用

页码：2 / 8

页数：7

共 44 条

[1]

[Anonymous], J CLIN ONCOL S

[2] Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay [J].

Arcila, Maria E. ;

Oxnard, Geoffrey R. ;

Nafa, Khedoudja ;

Riely, Gregory J. ;

Solomon, Stephen B. ;

Zakowski, Maureen F. ;

Kris, Mark G. ;

Pao, William ;

Miller, Vincent A. ;

Ladanyi, Marc .

CLINICAL CANCER RESEARCH, 2011, 17 (05) :1169-1180

[3] MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib [J].

Bean, James ;

Brennan, Cameron ;

Shih, Jin-Yuan ;

Riely, Gregory ;

Viale, Agnes ;

Wang, Lu ;

Chitale, Dhananjay ;

Motoi, Noriko ;

Szoke, Janos ;

Broderick, Stephen ;

Balak, Marissa ;

Chang, Wen-Cheng ;

Yu, Chong-Jen ;

Gazdar, Adi ;

Pass, Harvey ;

Rusch, Valerie ;

Gerald, William ;

Huang, Shiu-Feng ;

Yang, Pan-Chyr ;

Miller, Vincent ;

Ladany, Marc ;

Yang, Chih-Hsin ;

Pao, William .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (52) :20932-20937

[4] A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer [J].

Bertotti, Andrea ;

Migliardi, Giorgia ;

Galimi, Francesco ;

Sassi, Francesco ;

Torti, Davide ;

Isella, Claudio ;

Cora, Davide ;

Di Nicolantonio, Federica ;

Buscarino, Michela ;

Petti, Consalvo ;

Ribero, Dario ;

Russolillo, Nadia ;

Muratore, Andrea ;

Massucco, Paolo ;

Pisacane, Alberto ;

Molinaro, Luca ;

Valtorta, Emanuele ;

Sartore-Bianchi, Andrea ;

Risio, Mauro ;

Capussotti, Lorenzo ;

Gambacorta, Marcello ;

Siena, Salvatore ;

Medico, Enzo ;

Sapino, Anna ;

Marsoni, Silvia ;

Comoglio, Paolo M. ;

Bardelli, Alberto ;

Trusolino, Livio .

CANCER DISCOVERY, 2011, 1 (06) :508-523

[5] Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer [J].

Blackwell, Kimberly L. ;

Burstein, Harold J. ;

Storniolo, Anna Maria ;

Rugo, Hope ;

Sledge, George ;

Koehler, Maria ;

Ellis, Catherine ;

Casey, Michelle ;

Vukelja, Svetislava ;

Bischoff, Joachim ;

Baselga, Jose ;

O'Shaughnessy, Joyce .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1124-1130

[6] Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer [J].

Brugger, Wolfram ;

Triller, Nadja ;

Blasinska-Morawiec, Maria ;

Curescu, Stefan ;

Sakalauskas, Raimundas ;

Manikhas, Georgy Moiseevich ;

Mazieres, Julien ;

Whittom, Renaud ;

Ward, Carol ;

Mayne, Karen ;

Trunzer, Kerstin ;

Cappuzzo, Federico .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (31) :4113-4120

[7] Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study [J].

Cappuzzo, Federico ;

Ciuleanu, Tudor ;

Stelmakh, Lilia ;

Cicenas, Saulius ;

Szczesna, Aleksandra ;

Juhasz, Erzsebet ;

Esteban, Emilio ;

Molinier, Olivier ;

Brugger, Wolfram ;

Melezinek, Ivan ;

Klingelschmitt, Gaelle ;

Klughammer, Barbara ;

Giaccone, Giuseppe .

LANCET ONCOLOGY, 2010, 11 (06) :521-529

[8] Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design [J].

Chaft, Jamie E. ;

Oxnard, Geoffrey R. ;

Sima, Camelia S. ;

Kris, Mark G. ;

Miller, Vincent A. ;

Riely, Gregory J. .

CLINICAL CANCER RESEARCH, 2011, 17 (19) :6298-6303

[9] Evolving nonendocrine therapeutic options for metastatic breast cancer: How adjuvant chemotherapy influences treatment [J].

Conte, PierFranco ;

Guarneri, Valentina ;

Bengala, Carmelo .

CLINICAL BREAST CANCER, 2007, 7 (11) :841-849

[10] Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib [J].

Costa, Daniel B. ;

Nguyen, Kim-Son H. ;

Cho, Young C. ;

Sequist, Lecia V. ;

Jackman, David M. ;

Riely, GregoryJ. ;

Yeap, Beow Y. ;

Halmos, Balazs ;

Kim, Joo H. ;

Jaenne, Pasi A. ;

Huberman, Mark S. ;

Pao, William ;

Tenen, Daniel G. ;

Kobayashi, Susumu .

CLINICAL CANCER RESEARCH, 2008, 14 (21) :7060-7067

← 1 2 3 4 5 →